Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 CNS 1 Breast 1

Conditions

Interventions

Temozolomide 66 Radiotherapy 52 Carboplatin 25 Bevacizumab 21 Cisplatin 19 Radiosurgery 18 Vincristine 17 Etoposide 17 Cyclophosphamide 17 Surgical Procedures, Operative 13 Magnetic Resonance Spectroscopy 13 Chemotherapy, Adjuvant 11 Melphalan 10 Lomustine 10 Drug Therapy 10 Filgrastim 9 Erlotinib Hydrochloride 9 apatinib 8 Pemetrexed 8 3-Iodobenzylguanidine 8 anlotinib 7 Radiation 7 Peripheral Blood Stem Cell Transplantation 7 Methotrexate 7 Thiotepa 6 Isotretinoin 6 Irinotecan 6 Ifosfamide 6 Doxorubicin 6 Carmustine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × vistusertib × CNS × Clear all

NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡